Synthetic Biologics Inc.
| AMEX: SYN | Healthcare / Biotechnology / USA |
| 0.5300 | -0.0100 | -1.85% | Vol 41 080 | 1Y Perf -93.05% |
| Jun 24th, 2019 15:59 |
| BID | 0.0000 | ASK | 0.0000 | ||
| Open | 0.5500 | Previous Close | 0.5500 | ||
| Pre-Market | - | After-Trading | - | ||
| - -% | - -% |
| Target Price | 6.00 | Analyst Rating | — 0.00 | |
| Potencial % | 1 032.08 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12M | -100/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12M | -100/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12M | -100/-100/-100 | Income Ranking | — - | |
| Market Cap (mil) | 9 | Earnings Rating | Buy | |
| Price Range Ratio 52wk % | 0.46 | Earnings Date | 14th Aug 2019 |
Today's Price Range 0.53000.5500 | 52wk Range 0.49009.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Month | -3.64% | ||
| 3 Months | -22.06% | ||
| 6 Months | 1.92% | ||
| 1 Year | -93.05% | ||
| 3 Years | -99.11% | ||
| 5 Years | -99.11% |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | -61.90 | |||
ROE last 12 Months | -977.90 | |||
Return on Assets (5Y Avg) | -26.03 | |||
ROA last 12 Months | -141.56 | |||
Return on Capital (5Y Avg) | -635.81 | |||
ROC last 12 Months | -1 035.05 | |||
Return on invested Capital Q | -40.74 | |||
Return on invested Capital Y | -516.88 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 1.12 | |||
PS Ratio | - | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | -0.60 | |||
Cash Flow Per Share | -0.94 | |||
Price to Tangible Book | 1.12 | |||
Book Value per Share | 0.51 | |||
Enterprise Value (in ths.) | 2 184 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | 8.30 | |||
Current Ratio | 8.60 | |||
Long Term Debt to Total Capital | - | |||
Total Debt to Equity | - | |||
Interest Coverage | - | |||
| Leverage Ratio | 7.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | - | |||
EBIT Margin | - | |||
EBITDA Margin | - | |||
Pre-tax Profit Margin | - | |||
Profit Margin | - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (in ths.) | 0 | |||
Revenue per Share | 0.00 | |||
Revenue Growth 3 Years | - | |||
Revenue Growth 5 Years | - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2019 | - | -0.25 | - |
| Q04 2018 | -0.17 | -1.33 | -682.35 |
| Q03 2018 | -1.32 | -0.93 | 29.55 |
| Q02 2018 | -1.40 | -1.05 | 25.00 |
| Q01 2018 | -1.75 | -0.70 | 60.00 |
| Q04 2017 | -1.75 | 0.70 | 140.00 |
| Q03 2017 | -1.75 | -4.90 | -180.00 |
| Q02 2017 | -2.45 | -1.05 | 57.14 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2019 QR | -0.64 | -300.00 | Negative |
| 6/2019 QR | -0.61 | -281.25 | Negative |
| 12/2019 FY | -2.48 | -270.15 | Negative |
| 12/2020 FY | -2.54 | - | - |
| Next Report Date | 14th Aug 2019 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 41 080 |
| Shares Outstanding (in ths.) | 16 484 |
| Trades Count | 83 |
| Dollar Volume | 21 766 |
| Avg. Volume | 238 388 |
| Avg. Weekly Volume | 66 842 |
| Avg. Monthly Volume | 103 571 |
| Avg. Quarterly Volume | 133 320 |
Synthetic Biologics Inc.
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.
CEO: Steven A. Shallcross
Teplephone: +1 301 417-4364
Address: 9605 Medical Center Drive, Rockville 20850, MD, USA
